Product Images Budesonide

Figure 1 displays the results of a 12-week trial conducted in pediatric patients who were not receiving inhaled corticosteroid therapy before the study. The graph shows the change in nighttime asthma symptoms from baseline over the course of the 12 weeks. The x-axis represents the baseline and different time intervals (0-2 weeks, 2-4 weeks, etc.), while the y-axis represents the mean change in nighttime asthma symptoms. The graph includes data for three different treatment groups: placebo, 0.25 mg once daily, 0.5 mg once daily, and 1 mg once daily. The p-values are provided for the different treatment groups, indicating the statistical significance of the findings.*

This text describes a 12-week trial conducted on pediatric patients who were previously using inhaled corticosteroid therapy for asthma. The focus of the study was on the change in nighttime asthma symptoms from baseline. The mean change from baseline was observed and recorded at different time intervals throughout the trial. The trial involved three treatment groups: placebo, 0.25 mg twice daily, and 0.5 mg twice daily. The p-values for the two treatment groups were also mentioned, with the 0.25 mg group having a p-value of 0.022 and the 0.5 mg group having a p-value of 0.021.*